PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published this month in Nature Medicine and can be viewed online.
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of rCDI, which consists of a defined consortium of eight bacterial strains. Clinical results from Vedanta's successful Phase 2 CONSORTIUM study, published in the Journal of the American Medical Association (JAMA), demonstrated that the higher dose of VE303 studied was well tolerated and reduced the odds of CDI recurrence by more than 80% compared with placebo.
The new publication which is entitled 'Multi-omic Profiling a Defined Bacterial Consortium for Treatment of Recurrent Clostridioides difficile Infection,' reports additional results from CONSORTIUM. Profiling of microbiome composition, fecal metabolites, and host immune function indicated that VE303 works through multiple mechanisms to prevent rCDI by restoring a healthy gut microbial community, decreasing inflammation, and increasing levels of protective metabolites. In addition, the work identified predictors of high or low VE303 colonization and clinical response.
Taken together, these results demonstrate that VE303 works through multiple mechanisms to reduce CDI recurrence. Results from the CONSORTIUM study informed the design and dose selection for the global, pivotal Phase 3 study, RESTORATiVE303, that is currently underway to confirm the efficacy and safety profile of VE303 in the prevention of rCDI. Topline data for this study are expected in 2026.
The full text of the announcement from Vedanta is as follows:
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms
Analyses identified predictors of VE303 colonization and protection from CDI recurrence
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026
CAMBRIDGE, Mass., January 23, 2025 -- Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published this month in Nature Medicine and can be viewed online.
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of rCDI, which consists of a defined consortium of eight bacterial strains. Clinical results from Vedanta's successful Phase 2 CONSORTIUM study, published in the Journal of the American Medical Association (JAMA), demonstrated that the higher dose of VE303 studied was well tolerated and reduced the odds of CDI recurrence by more than 80% compared with placebo. VE303 organisms rapidly and robustly colonize the gut in a dose-dependent manner. Colonization predicted greater recurrence-free probability, establishing a direct connection between exposure and clinical response.
The publication which is entitled 'Multi-omic Profiling a Defined Bacterial Consortium for Treatment of Recurrent Clostridioides difficile Infection,' reports additional results from CONSORTIUM. Profiling of microbiome composition, fecal metabolites, and host immune function indicated that VE303 works through multiple mechanisms to prevent rCDI by restoring a healthy gut microbial community, decreasing inflammation, and increasing levels of protective metabolites. In addition, the work identified predictors of high or low VE303 colonization and clinical response.
'This clinical research offers new insights into the mechanisms of action of VE303, providing a rationale for the drug's protective effects in rCDI,' said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. 'Due to VE303's precisely known, defined composition, we can study its mechanisms of action and PK-PD relationships in a rigorous way, taking a step towards understanding why some patients respond better than others to a microbiome restoration intervention. We believe this line of work helps fill a knowledge gap in the field, since characterization of the mechanisms of action of first-generation fecal microbiota products has been very limited.'
Highlights of the publication include:
Abundance of specific VE303 strains, and of VE303 strains overall, was predictive of remaining recurrence-free.
The strains that colonized well differed across individuals, suggesting that efficacy is derived from strains working together as a consortium.
VE303 colonization and clinical benefit correlated with increased levels of short-chain fatty acids and key secondary bile acids, both of which have beneficial effects in conferring resistance to CDI.
Faster recovery of a more diverse microbiome, which was seen in the high dose recipients of VE303, was associated with non-recurrence.
The elimination rate of the antibiotic used for the CDI episode was a predictor of VE303 colonization. Given that clearance of residual antibiotic from stool varies significantly among individuals and can take a week or longer, treating with VE303 for 14 consecutive days following completion of standard-of-care antibiotics enabled VE303 strains to be inoculated when the intestinal environment was most permissive to colonization.
VE303 use led to lower levels of pro-inflammatory and potentially pathogenic Gram-negative species, including Klebsiella and Citrobacter, that are linked to CDI recurrence and AMR bacterial infections.
Taken together, these results demonstrate that VE303 works through multiple mechanisms to reduce CDI recurrence. Results from the CONSORTIUM study informed the design and dose selection for the global, pivotal Phase 3 study, RESTORATiVE303, that is currently underway to confirm the efficacy and safety profile of VE303 in the prevention of rCDI. Topline data for this study are expected in 2026.
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120C00177.
About VE303
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of recurrent Clostridioides difficile infection (rCDI). VE303 is an orally administered, defined bacterial consortium therapeutic candidate which consists of eight strains that were rationally selected using Vedanta's product engine. VE303 is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypass the need to rely on direct sourcing of donor fecal material of inconsistent composition. Vedanta published positive results in JAMA in April 2023 from the Phase 2 CONSORTIUM trial, in which VE303 met its primary endpoint of preventing C. difficile infection recurrence at eight weeks. Vedanta is currently enrolling patients into a Phase 3 RESTORATiVE303 registrational study of VE303 for the prevention of recurrent C. difficile infection. Vedanta Biosciences received a $5.4 million research grant from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) in 2017 and a contract of up to $81.9 million from Biomedical Advanced Research and Development Authority (BARDA) in 2020 to support clinical studies of VE303. VE303 was granted Orphan Drug Designation in 2017 by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent CDI.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company's lead assets are potential first-in-class oral therapies – VE303, in a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta's pipeline has been built using the company's industry-leading product engine for the development of therapies based on defined consortia of bacteria grown from pure clonal cell banks. The product engine, supported by broad foundational intellectual property, includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Vedanta's development plans for its pipeline of therapeutics of defined bacterial consortia as oral therapies for gastrointestinal diseases, including VE303, the timing of topline results for ongoing clinical trials, potential benefits to patients, and Vedanta's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Public Relations
[email protected]
[email protected] /EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
[email protected] Media
Justin Chen
+1 609 578 7230
[email protected]
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: PureTech Health plc
Copyright Business Wire 2025.
PUB: 01/27/2025 02:00 AM/DISC: 01/27/2025 02:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
12 hours ago
- Medscape
PROs Enhance Oncology Care Despite No OS Gain
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to briefly discuss a very important paper that recently appeared in Nature Medicine , entitled, 'Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.' I think those in the oncology community who are participating in clinical research are increasingly aware of how important, based upon trial design, patient-reported outcomes (PROs) are. Increasingly, this strategy is being considered for standard of care in academic medical centers, community oncology centers, and individual practices. Much of this enthusiasm comes out of the results of trials that have been reported in high-impact journals, which have suggested that, [in regards to] PROs, if you do this, you might actually improve survival in addition to improving quality of life. Very importantly, the studies that have been conducted to date have really focused more on the academic medical centers, the cancer centers, and unique patient populations. This study was an incredibly important follow-up trial from these earlier studies and really looked more at the population basis for the potential value of PROs. Again, this was a trial, but of course, we're looking at what the value may be outside of the clinical setting. This was a large, cluster-randomized trial looking at 52 oncology practices that were randomized to either do these surveys of symptom management or usual care without the survey. The PRO practice patients were invited to complete weekly symptom surveys. For severe or worsening symptoms, importantly, alerts were sent to the care team. Patients completed these weekly. If there was something that was severe or worsening, information went to the care team. Obviously, the individual practices that were not randomized to the PRO surveys did whatever program they might have had already. The primary outcome was an improvement in overall survival (OS), again, based upon previous studies. Secondary outcomes included emergency room visits, time to deterioration of physical function, health-related quality of life, and quite frankly, satisfaction with this tool — were they interested in it and did it seem beneficial. Here are the results. In all, 1191 patients were enrolled. In my opinion, not surprisingly, there was no difference in OS. Let me say, it would be very difficult to see in a study like this, with multiple different patient populations and a well-designed trial, that you could actually tease out an improvement in OS in a large patient population with all the other factors involved. For OS, surely there might be patients who are undergoing intensive chemotherapy or patients getting bone marrow transplantation where you might be able to really find a major impact on survival. In this large patient population, which is what we're focusing on here, a statistical improvement in OS would be difficult, but not the only important endpoint. Here are the rest of the results. The time to first emergency room visit was significantly prolonged in the patients who participated in the PRO survey. There was a 6% decrease overall in the emergency room visits — think of the time and effort for patients and cost that was eliminated. There were fewer overall visits at 12 months. The use of the symptom survey significantly delayed the deterioration in physical function symptoms and improved health-related quality of life. These are critically important issues, every one of them, for the practice of oncology and our goals. In addition, 77% of patients felt that the PRO survey tool improved their discussions with their care team and made them feel more in control of their own care. As evidence of the value here, 91.5% of the patients completed — on a weekly basis — these survey estimates. If they weren't interested and they didn't think it of value, surely that number would've been much lower. Again, this is a very important study. The investigators said they're planning on doing additional studies not focusing on OS as the primary endpoint, which I certainly agree with. The results are very important, and clearly, this is the type of strategy that we need to consider cost-effective ways for implementation in our routine care. Thank you for your attention.
USA Today
17 hours ago
- USA Today
Improving gut health can do more than help digestion
While most of us only think of our digestive system as helping to process the foods we eat or being behind the occasional stomach ache, a healthy gut can also impact everything from stronger immunity to improved sleep quality, anxiety management or a boosted mood. That's because behind every gurgle and growl there's a bustling ecosystem of trillions of microorganisms that include bacteria, viruses and fungi that can all affect overall mental and physical well-being. When any balance is disrupted though, the effects can ripple throughout the entire body. 'People often underestimate how much of their overall health is linked to the gut,' says Lisa Young, a registered dietitian nutritionist, author of "Finally Full, Finally Slim" and an adjunct professor of nutrition at New York University. 'And even if you don't have obvious digestive symptoms, your gut could still be out of balance.' Fortunately, improving your gut health doesn't require expensive supplements or extreme diets. Simple lifestyle and dietary changes are usually all that is needed to get back on track when things go awry. What is gut health? Gut health refers to the optimal functioning of the digestive system, specifically the gastrointestinal (GI) tract and the trillions of microbes that live within it, known as the gut microbiome. 'When people talk about gut health, they're usually referring to the balance of this microbiome,' explains Young. For optimal balancing, remember that "a healthy gut has an abundance of 'good' bacteria while an unhealthy gut has more 'bad' bacteria,' says Dr. Uma Naidoo, director of nutritional and lifestyle psychiatry at Massachusetts General Hospital and the Harvard-trained nutritional psychiatrist behind "Calm Your Mind with Food." A few of the "good" bacteria that improve gut health include: Such bacteria play key roles not only in digestion but in inflammation regulation, mental health and chronic disease prevention. Harmful bacteria, on the other hand, include Clostridioides difficile, Staphylococcus and Escherichia coli and can collectively or individually cause damage or imbalance to the gut microbiome. At the same time, everyone's GI system won't respond to good or bad bacteria the same way and individual stressors and exposure to environmental toxins like tobacco smoke and air pollution can also play significant roles in overall gut health. "The microbiome is unique to each individual," says Kelly Jones, a registered performance dietitian and the founder of Student Athlete Nutrition. "It's influenced by everything from diet to stress to pollutant exposure,' she explains. Hmm: An apple a day really can help keep the doctor away. Here's how. How do you know your gut is unhealthy? Some of the signs of an unhealthy gut are obvious while others are more complex. "An imbalanced gut can contribute to a wide range of common stomach issues including bloating, gas, constipation, diarrhea and food intolerances,' says Young. Other times, she adds, signs of poor gut health include things we don't think of as being associated with our gastrointestinal system. These can include skin problems, difficulty losing weight and even anxiety or depression. Other signs to look out for of your gut needing some TLC include getting sick more often than usual, diminished energy levels and difficulty concentrating, says Jones. When issues persist over extended periods of time, more serious signs may arise. "A chronically unhealthy gut can lead to a 'leaky gut,' where the lining of the gut becomes permeable and allows harmful substances to pass into the bloodstream, causing systemic inflammation and chronic disease," cautions Naidoo. Depleted energy levels affect us all. But here's when they could indicate something serious. How to improve gut health? How to heal your gut? Improving gut health begins with addressing the lifestyle or dietary choices that cause damage or gut imbalances to occur. Here are some tips: As helpful as each of these recommendations can be individually, it's the combination of factors that will yield the best results. 'A healthy gut is truly the foundation for overall health,' says Young.
Business Upturn
a day ago
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
